New FDA Approved Drug to Help Type 2 Diabetes

For Immediate Release: March 29, 2013
Media Inquiries: Morgan Liscinsky, 301-796-0397;
Consumer Inquiries: 888-INFO-FDA

FDA approves Invokana to treat type 2 diabetes
First in a new class of diabetes drugs

The U.S. Food and Drug Administration today approved Invokana (canagliflozin) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.

Type 2 diabetes is the most common form of the disease, affecting about 24 million people and accounting for more than 90 percent of diabetes cases diagnosed in the United States. Over time, high blood sugar levels can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage.

“Invokana is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors,” said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “We continue to advance innovation with the approval of new drug classes that provide additional treatment options for chronic conditions that impact public health.”

Invokana works by blocking the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetics who have elevated blood glucose levels. Its safety and effectiveness were evaluated in nine clinical trials involving over 10,285 patients with type 2 diabetes. The trials showed improvement in hemoglobin A1c levels (a measure of blood sugar control) and fasting plasma glucose (blood sugar) levels.

Invokana has been studied as a stand-alone therapy and in combination with other type 2 diabetes therapies including metformin, sulfonylurea, pioglitazone, and insulin. Invokana should not be used to treat people with type 1 diabetes; in those who have increased ketones in their blood or urine (diabetic ketoacidosis); or in those with severe renal impairment, end stage renal disease, or in patients on dialysis.

The FDA is requiring five postmarketing studies for Invokana: a cardiovascular outcomes trial; an enhanced pharmacovigilance program to monitor for malignancies, serious cases of pancreatitis, severe hypersensitivity reactions, photosensitivity reactions, liver abnormalities, and adverse pregnancy outcomes; a bone safety study; and two pediatric studies under the Pediatric Research Equity Act (PREA), including a pharmacokinetic and pharmacodynamic study and a safety and efficacy study.

The most common side effects of Invokana are vaginal yeast infection (vulvovaginal candidiasis) and urinary tract infection. Because Invokana is associated with a diuretic effect, it can cause a reduction in intravascular volume leading to orthostatic or postural hypotension (a sudden fall in blood pressure when standing up). This may result in symptoms such as dizziness or fainting, and is most common in the first three months of therapy.

Invokana is manufactured for Janssen Pharmaceuticals, Inc., Titusville, N.J.

For more information:

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Republished 3/30/13 1120 hours PST

About The NW Fire Blog (TM)

This online Fire Blog is solely written by LR Swenson, Author of Short Story, "Seattle Mourn" published in the anthology, "Felons, Flames and Ambulance Rides" released in July 2013. Her Flash Fiction story, "The Firefighter and The Princess" received an Honorable Mention from the Public Safety Writers Association in July 2013 as well. Her extensive skills, knowledge and non-profit experience comes from participating in many Human Services related organizations such as: SAR K9 groups, Disaster SAR, serving in various capacities as [President, Co-President and Secretary], EOC Support, Fire Photographer, Newsletter writer and assisting with Firefighter REHAB [Canteen Services] until 2012. Instilled with her love for writing, she created a Blog from scratch, turning it into a success story. She credits the many friends she has met along the way to providing encouragement, support and lots of great feedback. The NW Fire Blog is all about Everything that has to do with Public Safety, the professionals, volunteers and those who support the great two most important Missions in Life: Saving Lives, So That Others May Live and To Protect and Serve. This is why LR Swenson has created this Blog. Thank you for stopping by. Please check us out on our Social Media pages at: @nwfireblog - Twitter The NW Fire Blog - Facebook - Email
This entry was posted in FDA, Health. Bookmark the permalink.